Us Bancorp \De\ Viridian Therapeutics, Inc.\De Transaction History
Us Bancorp \De\
- $78.3 Billion
- Q2 2025
A detailed history of Us Bancorp \De\ transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Us Bancorp \De\ holds 1,994 shares of VRDN stock, worth $35,832. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,994
Previous 1,490
33.83%
Holding current value
$35,832
Previous $20,000
35.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding VRDN
# of Institutions
185Shares Held
79.7MCall Options Held
84.1KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$96.7 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$85.8 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$84.5 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$81 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$69.8 Million12.64% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $717M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...